▲ BUY
9
/ 10
Conviction
$ Value
$49K
Shares
10,000
Price
$5
Filed
Mar 18
▶ Why this score? (9/10)
- ✓ Open market buy (+3)
- ✓ % of holdings >= 20% (+2)
- ✓ Director (+1)
- ✓ Cluster: 4 insiders buying (+2)
- ✓ Not a 10b5-1 plan (+1)
Insider
Name
DENELSKY STEPHEN J
Title
—
CIK
0001204320
Roles
Director
Transaction Details
Transaction Date
2026-03-17
Code
P
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
21,000
Footnotes
Includes (a) 10,000 shares of common stock purchased on March 17, 2026 and (b) 11,000 restricted stock units that fully vest on September 5, 2026. | On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 1(b) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.
Filing Info
Other Insiders at HBIO (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| Snider William | $104K | — | 2026-03-17 |
|
Duke John D
Chief Executive Officer
|
$25K | — | 2026-03-20 |
|
Frost Mark T
Chief Financial Officer
|
$25K | — | 2026-03-20 |